Literature DB >> 25027180

A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.

Christoph B Olivier1, Katharina Schnabel, Christoph Brandt, Patrick Weik, Manfred Olschewski, Qian Zhou, Christoph Bode, Philipp Diehl, Martin Moser.   

Abstract

OBJECTIVE: This study aimed to evaluate whether a high relative ADP induced aggregation (r-ADP-agg) is associated with an increased mortality in patients after coronary stent implantation.
BACKGROUND: Several trials were not able to improve clinical outcome by adapting platelet inhibition in patients after coronary stent implantation and high platelet reactivity (HPR). Platelet monitoring is complex and conventional definition of adenosindiphosphate (ADP) induced aggregation alone might not transfer the whole picture of adequate platelet inhibition in vivo.
METHODS: In a prospective single-centre observational trial multiple electrode aggregometry was performed in whole blood of patients after stent implantation. r-ADP-agg was defined as the ADP-thrombin receptor activating peptide ratio to reflect an individual degree of P2Y12 dependent platelet inhibition with a cut-off value for HPR of ≥ 50%. The primary end point was mortality.
RESULTS: Follow-up was completed in 176 of 184 patients (96%) with a mean follow-up time of 3.7 years. 35 (20 %) patients revealed an r-ADP-agg ≥ 50%. An r-ADP-agg ≥ 50% was associated with an increased mortality [unadjusted hazard ratio (HR) 7.006 (2.561-19.17); p = 0.0001]. In a multivariable Cox regression analysis mortality was independently associated with an r-ADP-agg ≥ 50% [HR 3.324 (1.542-7.165); p = 0.0022], ACS-setting [HR 3.249 (1.322-7.989); p = 0.0102] and severely reduced LV function [HR 5.463 (2.098-14.26); p = 0.0005].
CONCLUSION: An r-ADP-agg ≥ 50% is associated with an increased mortality in patients after coronary stent implantation. Furthermore, r-ADP-agg might represent a better tool to predict clinical outcome than the conventional ADP induced platelet aggregation alone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027180     DOI: 10.1007/s00392-014-0737-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  30 in total

1.  Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.

Authors:  Thomas Gremmel; Sabine Steiner; Daniela Seidinger; Renate Koppensteiner; Simon Panzer; Christoph W Kopp
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

2.  Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.

Authors:  Spyridon Liosis; Timm Bauer; Rudolf Schiele; Helmut Gohlke; Martin Gottwik; Hugo Katus; Georg Sabin; Ralf Zahn; Steffen Schneider; Bernhard Rauch; Jochen Senges; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2013-06-06       Impact factor: 5.460

3.  Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?

Authors:  Thomas Gremmel; Andreas Calatzis; Sabine Steiner; Alexandra Kaider; Daniela Seidinger; Renate Koppensteiner; Christoph W Kopp; Simon Panzer
Journal:  Platelets       Date:  2010       Impact factor: 3.862

4.  Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.

Authors:  Uwe Zeymer; Hans-Richard Arntz; Bernd Mark; Stephan Fichtlscherer; Gerald Werner; Ralph Schöller; Ralf Zahn; Frank Diller; Harald Darius; Thorsten Dill; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2011-12-21       Impact factor: 5.460

5.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.

Authors:  Iris Müller; Felicitas Besta; Christian Schulz; Steffen Massberg; Albert Schönig; Meinrad Gawaz
Journal:  Thromb Haemost       Date:  2003-05       Impact factor: 5.249

6.  Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation.

Authors:  Philipp Diehl; Christoph Halscheid; Christoph Olivier; Thomas Helbing; Christoph Bode; Martin Moser
Journal:  Clin Res Cardiol       Date:  2011-04-09       Impact factor: 5.460

7.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

8.  Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

Authors:  Francesco Sofi; Rossella Marcucci; Anna Maria Gori; Betti Giusti; Rosanna Abbate; Gian Franco Gensini
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

9.  Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines.

Authors:  Renee Stark; Inge Kirchberger; Matthias Hunger; Margit Heier; Reiner Leidl; Wolfgang von Scheidt; Christa Meisinger; Rolf Holle
Journal:  Clin Res Cardiol       Date:  2013-11-28       Impact factor: 5.460

10.  Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.

Authors:  Ulrike Theidel; Christian Asseburg; Evangelos Giannitsis; Hugo Katus
Journal:  Clin Res Cardiol       Date:  2013-03-09       Impact factor: 5.460

View more
  5 in total

Review 1.  [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].

Authors:  C B Olivier; P Diehl; C Bode; M Moser
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

2.  High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.

Authors:  Jonathan Rilinger; Melanie Meyer; Katharina Schnabel; Patrick Weik; Anne Charlet; Jennifer S Esser; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl; Christoph B Olivier
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

3.  Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.

Authors:  Christoph B Olivier; Katharina Schnabel; Susanne Weber; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

4.  Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.

Authors:  Eva-Luise Hobl; Birgit Reiter; Christian Schoergenhofer; Michael Schwameis; Ulla Derhaschnig; Irene Marthe Lang; Thomas Stimpfl; Bernd Jilma
Journal:  Clin Res Cardiol       Date:  2015-10-22       Impact factor: 5.460

5.  The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.

Authors:  Christoph B Olivier; Melanie Meyer; Hans Bauer; Katharina Schnabel; Patrick Weik; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.